Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Hurkmans · SciRah

Researcher profile · Semantic Scholar

D. Hurkmans

Share profile

D. Hurkmans — researcher profile on SciRah

h-index: 17
Works: 46
Citations: 928

Most-cited papers

High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
L. Cantini, Federica Pecci, D. Hurkmans, R. Belderbos +9 more
2020European Journal of Cancer103 citations Open access
Semantic Scholar
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients
D. Hurkmans, M. Kuipers, Jasper Smit, R. van Marion +6 more
2020Cancer Immunology and Immunotherapy88 citations Open access
Semantic Scholar
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
D. Hurkmans, E. A. Basak, Tanja C. van Dijk, D. Mercieca +12 more
2019Journal of Immunotherapy for Cancer84 citations Open access
Semantic Scholar
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
E. A. Basak, J. V. D. van der Meer, D. Hurkmans, M. Schreurs +10 more
2020Thyroid75 citations
Semantic Scholar
Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
E. A. Basak, S. Koolen, D. Hurkmans, M. Schreurs +9 more
2019European Journal of Cancer69 citations
Semantic Scholar
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer
D. Hurkmans, E. A. Basak, N. Schepers, Esther Oomen-de Hoop +10 more
2020Journal for ImmunoTherapy of Cancer67 citations Open access
Semantic Scholar
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
André Kunert, E. A. Basak, D. Hurkmans, H. E. Balcioglu +11 more
2019Journal of Immunotherapy for Cancer58 citations Open access
Semantic Scholar
Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
D. Hurkmans, C. Jensen, S. Koolen, J. Aerts +3 more
2020Journal for ImmunoTherapy of Cancer46 citations Open access
Semantic Scholar
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
K. Hussaarts, D. Hurkmans, Esther Oomen-de Hoop, L. V. van Harten +10 more
2019Cancers46 citations Open access
Semantic Scholar
The prognostic value of weight and body composition changes in patients with non‐small‐cell lung cancer treated with nivolumab
J. Degens, A. Dingemans, A. C. H. Willemsen, H. Gietema +4 more
2021Journal of Cachexia, Sarcopenia and Muscle42 citations Open access
Semantic Scholar
Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment
D. Hurkmans, J. Verhoeven, K. de Leur, K. Boer +7 more
2019Journal of Immunotherapy for Cancer37 citations Open access
Semantic Scholar
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types
N. Willumsen, C. Jensen, G. Green, N. Nissen +21 more
2022Cellular and Molecular Life Sciences32 citations Open access
Semantic Scholar
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Jinfeng Cao, N. J. Brouwer, Kate E. Richards, M. Marinkovic +5 more
2017OncoTarget30 citations Open access
Semantic Scholar
Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis
D. T. ten Berge, D. Hurkmans, Ilse den Besten, J. Kloover +4 more
2019ERJ Open Research24 citations Open access
Semantic Scholar
A Serum Protein Classifier Identifying Patients with Advanced Non–Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
M. Muller, K. Hummelink, D. Hurkmans, A. Niemeijer +6 more
2020Clinical Cancer Research21 citations Open access
Semantic Scholar
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
D. Hurkmans, E. Verdegaal, S. Hogan, R. de Wijn +17 more
2020Journal for ImmunoTherapy of Cancer19 citations Open access
Semantic Scholar
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
D. Hurkmans, S. Sassen, K. de Joode, Lisanne Putter +11 more
2021Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study.
E. A. Basak, N. Vermeer, K. de Joode, D. Hurkmans +10 more
2022European Journal of Cancer17 citations Open access
Semantic Scholar
Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
M. de With, D. Hurkmans, Esther Oomen-de Hoop, A. Lalouti +8 more
2021Cancers16 citations Open access
Semantic Scholar
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
Jinfeng Cao, N. J. Brouwer, Kate E. Richards, M. Marinkovic +5 more
2017OncoTarget14 citations Open access
Semantic Scholar
Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?
E. V. D. van de Garde, L. R. van Bedaf, D. Hurkmans, M. van den Heuvel
2020Annals of Oncology7 citations Open access
Semantic Scholar
Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma and non-small cell lung cancer.
L. Cantini, Federica Pecci, D. Hurkmans, C. Copparoni +8 more
2020Journal of Clinical Oncology6 citations
Semantic Scholar
Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
G. D. Marijn Veerman, D. Hurkmans, M. Paats, Esther Oomen-de Hoop +6 more
2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie4 citations Open access
Semantic Scholar
Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
D. Hurkmans, M. Tamminga, B. van Es, T. Peters +12 more
2020Lung Cancer3 citations Open access
Semantic Scholar
Correlation between nivolumab exposure and treatment outcome in NSCLC.
S. Koolen, E. A. Basak, D. Hurkmans, M. Schreurs +9 more
20182 citations
Semantic Scholar
1335P The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)
M. Hofman, B. C. Agema, J. Degens, D. Hurkmans +12 more
2024Annals of Oncology1 citations
Semantic Scholar
P2.04-47 Tumor Mutational Load, CD8+ T Cells, Expression of PD-L1 and HLA Class I to Guide Immunotherapy Decisions
D. Hurkmans, M. Kuipers, Jasper Smit, R. Van Marion +6 more
2019Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Blood-based multiplex kinase activity profiling as a predictive marker for clinical response to checkpoint blockade in advanced melanoma.
D. Hurkmans, E. Verdegaal, Sabrina Schindler, E. A. Basak +12 more
20181 citations
Semantic Scholar
Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study
K. de Joode, H. Groen, M. van den Heuvel, J. Kloover +14 more
2026Journal for ImmunoTherapy of Cancer0 citations Open access
Semantic Scholar
Re: Policy Versus Practice: Facilitators and Barriers of Chronic Care Integration in Dutch General Practice – a Survey Study
D. Hurkmans, Eva de Bie
2026International Journal of Integrated Care0 citations
Semantic Scholar
Impact of a diagnostic strategy for appendicitis in children with acute abdominal pain in primary care: study protocol for a hybrid type 1 cluster randomised controlled trial
Esmee M Hogervorst, R. Venekamp, G. E. Knol-de Vries, T. Platteel +22 more
2026Diagnostic and Prognostic Research0 citations Open access
Semantic Scholar
Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.
K. de Joode, H. E. Balcioglu, M. van Brakel, M. T. López-Cascales +8 more
2026Journal of Immunology0 citations Open access
Semantic Scholar
1883P Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: The prospective IOpener study
K. Joode, H. Groen, M. M. van den Heuvel, J. Kloover +14 more
2025Annals of Oncology0 citations Open access
Semantic Scholar
Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.
K. de Joode, H. Groen, M. van den Heuvel, J. Kloover +14 more
2024Journal of Clinical Oncology0 citations Open access
Semantic Scholar
860P The IOpener study: Tyrosine kinase activity in peripheral lymphocytes to predict durable response to immune checkpoint inhibition in patients with advanced melanoma
K. de Joode, K. Suijkerbuijk, J. D. de Groot, A. V. D. van der Veldt +14 more
2022Annals of Oncology0 citations Open access
Semantic Scholar
31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer
K. Joode, H. J. M. Groen, M. M. van den Heuvel, J. Kloover +16 more
2022Immuno-Oncology and Technology0 citations Open access
Semantic Scholar
1902P Association of high-intensity statins with clinical outcome in malignant pleural mesothelioma and advanced non-small cell lung cancer patients treated with PD1 inhibitors
L. Cantini, Federica Pecci, A. Lanese, D. Hurkmans +9 more
20200 citations Open access
Semantic Scholar
1128P Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy
M. de With, D. Hurkmans, E. O. Hoop, A. Lalouti +7 more
20200 citations Open access
Semantic Scholar
100P Evaluation of the circulating stromal biomarker VICM reflecting M1-like macrophage activity in metastatic melanoma patients treated with anti-PD-1 therapy
C. Jensen, D. Hurkmans, S. Koolen, J. Aerts +3 more
20200 citations Open access
Semantic Scholar
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
C. Jensen, D. Hurkmans, S. Koolen, M. Karsdal +2 more
20200 citations
Semantic Scholar
P1.09-21 Tumor Responses Based on Tumor Growth Rate During PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients
D. T. ten Berge, D. Hurkmans, I. Den Besten, J. Kloover +4 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
P2.04-06 Blood-Based Multiplex Kinase Activity Profiling as a Predictive Marker for Clinical Response to Checkpoint Blockade in Advanced NSCLC
D. Hurkmans, E. Verdegaal, R. de Wijn, S. Koolen +8 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
Gerardus Hussaarts, D. Hurkmans, E. O. Hoop, L. V. van Harten +10 more
20180 citations
Semantic Scholar
Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.
André Kunert, E. A. Basak, D. Hurkmans, Y. Klaver +10 more
20180 citations
Semantic Scholar
Whole Genome Sequencing in Personalized Oncology - Poster
V. Retèl, W. V. van Harten, M. Joore, M. IJzerman +23 more
2017EUR Research Repository (Erasmus University Rotterdam)0 citations Open access
Semantic Scholar
Expression of PD-L1 and PD-1 in conjunctival melanoma
Jinfeng Cao, Kate E. Richards, E. Jordanova, M. Arinkovic +4 more
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Aerts×32
Invite
J. Aerts — researcher profile on SciRah
R. Mathijssen×27
Invite
R. Mathijssen — researcher profile on SciRah
R. Debets×17
Invite
R. Debets — researcher profile on SciRah
S. Koolen×15
Invite
S. Koolen — researcher profile on SciRah

×12

Invite

E. A. Basak — researcher profile on SciRah

A. V. D. van der Veldt×12

Invite

A. V. D. van der Veldt — researcher profile on SciRah

Invite

S. Bins — researcher profile on SciRah

E. Verdegaal×10

Invite

E. Verdegaal — researcher profile on SciRah

Esther Oomen-de Hoop×8

Invite

Esther Oomen-de Hoop — researcher profile on SciRah

Invite

R. de Wijn — researcher profile on SciRah

D. V. D. van den Heuvel×8

Invite

D. V. D. van den Heuvel — researcher profile on SciRah

Invite

J. Groten — researcher profile on SciRah